Compare Medtronic PLC (MDT) vs Newmont Corporation (NEM) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

Newmont Corporation (NEM) trades at $89.52, down 0.2% over 24 hours, with technical indicators showing a bearish trend. The company reported strong fundamentals with Q1 2026 EPS of $2.90 beating expectations of $2.07, revenue growth to $22.67 billion in 2025, and robust cash flow from operations of $10.33 billion. Analyst sentiment remains overwhelmingly positive with 28 buy ratings and a consensus price target of $139.22, suggesting significant upside potential from current levels.

The outlook for Newmont is favorable due to strong earnings momentum, attractive valuation multiples (P/E of 11.63), and projected revenue growth to $25.0 billion in 2026. Key risks include exposure to gold price volatility, rising unit costs pressuring margins, and execution challenges in production growth. The stock presents a compelling opportunity for value-oriented investors given the disconnect between current price and analyst targets.